Glycobreez F DPI Capsule is a combination bronchodilator containing Formoterol (12 mcg) and Glycopyrrolate (25 mcg), indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. Formoterol, a long-acting beta2-adrenergic agonist (LABA), facilitates bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as dyspnea and wheezing. Glycopyrrolate, a long-acting muscarinic antagonist (LAMA), complements this effect by inhibiting acetylcholine-mediated bronchoconstriction, leading to sustained airway relaxation. The dry powder inhaler (DPI) formulation ensures targeted delivery to the lungs, enhancing therapeutic efficacy while minimizing systemic exposure. Glycobreez F DPI Capsule is typically administered twice daily and is intended for maintenance therapy rather than acute symptom relief. It is essential to use this medication under medical supervision, as inappropriate use may lead to adverse effects such as tachycardia, dry mouth, or paradoxical bronchospasm. Patients should be advised to continue their prescribed regimen and not to discontinue therapy abruptly. This combination therapy offers a synergistic approach to improving lung function, reducing exacerbations, and enhancing quality of life in patients with moderate to severe COPD.